Article Details
Retrieved on: 2022-06-10 18:57:54
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Patients receiving baricitinib also showed lower 28-day mortality compared with the remdesivir monotherapy control group of 5.1% and 7.8%, ...
Article found on: community99.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here